Scientists have discovered several new mutations in the KRAS gene that could affect patients' responses to cancer therapies. KRAS testing is already performed in colorectal cancer patients, as those with mutations in the gene do not respond to EGFR inhibitor drugs such as Amgen's ...
Please Login to read the full article.
